Sagawa S, Ito F, Nakatani M, Kurose S, Niiro E, Taniguchi M, Toyoda S, Sado T, Morita K. Mesonephric-like adenocarcinoma presenting with malignant peritonitis and suspected to originate from the fallopian tube: A case report. World J Clin Cases 2025; 13(32): 110813 [DOI: 10.12998/wjcc.v13.i32.110813]
Corresponding Author of This Article
Shoko Sagawa, Department of Obstetrics and Gynecology, Nara Prefecture General Medical Center, Shichijo-Nishimachi 2-chome 897-5, Nara 630-8581, Japan. shosgw3a.39.goodjob@gmail.com
Research Domain of This Article
Obstetrics & Gynecology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nov 16, 2025 (publication date) through Nov 15, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Sagawa S, Ito F, Nakatani M, Kurose S, Niiro E, Taniguchi M, Toyoda S, Sado T, Morita K. Mesonephric-like adenocarcinoma presenting with malignant peritonitis and suspected to originate from the fallopian tube: A case report. World J Clin Cases 2025; 13(32): 110813 [DOI: 10.12998/wjcc.v13.i32.110813]
Shoko Sagawa, Fuminori Ito, Sonomi Kurose, Emiko Niiro, Makiko Taniguchi, Shinji Toyoda, Toshiyuki Sado, Department of Obstetrics and Gynecology, Nara Prefecture General Medical Center, Nara 630-8581, Japan
Masahide Nakatani, Department of Obstetrics and Gynecology, Nara Medical University, Kashihara 634-8521, Nara, Japan
Kohei Morita, Department of Pathology, Nara Prefecture General Medical Center, Nara 630-8581, Japan
Co-corresponding authors: Shoko Sagawa and Fuminori Ito.
Author contributions: Sagawa S analyzed the data and wrote the manuscript; Ito F designed the report and determined the clinical significance of the case; Sagawa S and Ito F played a key role in writing the paper; Nakatani M collected and analyzed the clinical, imaging, and pathological data; Kurose S, Niiro E, and Taniguchi M treated the patient in this case; Toyoda S and Sado T supervised the clinical interpretation and manuscript development; Morita K made the histopathological diagnosis of this case; All authors have read and approved the final manuscript. Sagawa S and Ito F are equally responsible for the integrity of the paper and are designated as co-corresponding authors.
Informed consent statement: Written informed consent was obtained from the patient for publication of this case report and accompanying images.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shoko Sagawa, Department of Obstetrics and Gynecology, Nara Prefecture General Medical Center, Shichijo-Nishimachi 2-chome 897-5, Nara 630-8581, Japan. shosgw3a.39.goodjob@gmail.com
Received: June 17, 2025 Revised: July 21, 2025 Accepted: September 25, 2025 Published online: November 16, 2025 Processing time: 149 Days and 21.8 Hours
Abstract
BACKGROUND
Mesonephric-like adenocarcinoma (MLA) is a rare and highly malignant disease that occurs in the uterine body or ovaries. We report a case of a MLA that was considered to have originated in the fallopian tube and presented with malignant peritonitis.
CASE SUMMARY
A 57-year-old female presented with a chief complaint of abdominal pain that began 2 months prior. Cancerous peritonitis was suspected. During exploratory laparoscopy, the right fallopian tube was found to be enlarged, with widespread disseminated lesions extending from the pelvic cavity to the upper abdomen. Histopathological examination of the peritoneal tissue obtained by biopsy showed tumor cells with a high nuclear/cellular ratio and proliferation of papillary tubular to pedunculated solid nests. Immunohistochemical testing was positive for GATA-binding protein 3, thyroid transcription factor 1, cluster of differentiation 10, and paired box protein-8, and negative for estrogen receptor, Wilms’ tumor 1, and wild-type p53, leading to the diagnosis of MLA. Subsequently, debulking surgery was performed, and no macroscopic residual tumors were identified. The pathological diagnosis was right tubal carcinoma, mesonephric adenocarcinoma (International Federation of Gynecology and Obstetrics stage IIIC), and pT3cNXM0. Adjuvant chemotherapy was administered postoperatively; however, recurrence was noted, and the patient died 1 year and 6 months after the initial treatment.
CONCLUSION
MLA is a very rare disease with poor prognosis. Further studies are necessary to identify effective treatment options.
Core Tip: Mesonephric-like adenocarcinoma (MLA) is a highly aggressive rare disease. There have been few reports of MLA occurring primarily in the fallopian tube. MLA is primarily diagnosed by immunohistochemical staining. We report a case of MLA originating from the fallopian tube; the patient died 1 year and 6 months after initial treatment. Effective treatment options for MLA in the fallopian tubes are urgently needed. The presence of Kirsten rat sarcoma virus mutation is a notable characteristic when considering specific treatments for MLAs.
